Iambic Therapeutics (NASDAQ:IAM – Get Free Report) was upgraded by research analysts at Wall Street Zen to a “hold” rating in a research note issued on Saturday, Wall Street Zen reports.
Iambic Therapeutics Trading Down 12.6%
NASDAQ:IAM opened at $10.17 on Friday. Iambic Therapeutics has a one year low of $9.60 and a one year high of $25.00.
Insider Buying and Selling
In related news, Director Evan Lockwood Rachlin purchased 718,750 shares of Iambic Therapeutics stock in a transaction on Friday, October 16th. The shares were bought at an average price of $16.00 per share, with a total value of $11,500,000.00. Following the transaction, the director directly owned 2,588,248 shares of the company’s stock, valued at approximately $41,411,968. This trade represents a 38.45% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 22.90% of the stock is currently owned by corporate insiders.
Iambic Therapeutics Company Profile
Featured Stories
- Five stocks we like better than Iambic Therapeutics
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
- MarketBeat Week in Review – 11/2 – 11/6
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
